COVID-19 and microsampling: from patient-centric testing to drug development and beyond

Recently the National Institutes of Health (MD, USA) announced a study to quantify undetected cases of COVID-19 using antibody tests on blood samples collected in microsampling devices [1]. We asked microsampling expert Hua Li (Boehringer Ingelheim Pharmaceuticals, CT, USA) for her perspectives on the potential benefits and applications of patient-centric microsampling strategies amidst the coronavirus pandemic. You can read more about Hua’s research using the Mitra® microsampling platform for pharmacokinetic bioanalysis in her Bioanalysis publication. “I majored in Biotechnology in college back in China and then earned a Master’s degree in Molecular, Cellular and Developmental Biology from the University of...

To view this content, please register now for access

It's completely free